Attention Deficit Hyperactivity DisorderPhase 4NCT02545634
Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children
A Phase 4 study testing L. helveticus R0052 and B. longum R0175 in people with Attention Deficit Hyperactivity Disorder and Anxiety, run by Acadia University at 1 site in Canada.
Trial summary
The study will examine the effect of a probiotic supplement (Lactobacillus helveticus R0052 and Bifidobacterium Longum R0175) dissolved in a dairy product such as milk or ice-cream on symptoms of ADHD and anxiety in children. Read more about this study
- Who is it for?
- Ages 6 to 14 years
- Conditions the study is for
- Attention Deficit Hyperactivity Disorder, Anxiety
- What is being tested?
- L. helveticus R0052 and B. longum R0175
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteCanada
- Study dates
- Jun 2015to Jun 2016
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 14 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- average score of 2.5 or higher on either the hyperactive/impulsive or inattentive symptoms on eligibility questionnaire
- total score of 10 or higher on the anxiety eligibility questionnaire
Who cannot join
- Dairy or Soy allergy
- Currently taking antibiotics
- HIV/AIDS
- Diagnosis of Cancer, Crohn's Disease, or Ulcerative Colitis
- Undergoing chemotherapy
Trial locations and contacts
1 site in 1 country.
Canada1 site, 1 recruiting
- Recruiting
Acadia University
Wolfville, Nova Scotia, B4P 2R6
Susan Potter, Phd., 902-585-1220, susan.potter@acadiau.ca
Patrick Bazinet, BAh, 9027903548, bazinet.patrick@gmail.com
About this study
Official title: Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children
The study will examine the effect of a probiotic supplement (Lactobacillus helveticus R0052 and Bifidobacterium Longum R0175) dissolved in a dairy product such as milk or ice-cream on symptoms of ADHD and anxiety in children. The main goal is to determine if probiotics might be useful as a treatment for anxiety and ADHD symptoms in children. A second goal is to examine the effects of probiotics on saliva cortisol levels. Finally, the investigators are also interested in the effects of the probiotics on children's digestive health.
Read the detailed description
Participants will be recruited using information distributed through schools in the Annapolis Valley area and with the use of advertising campaigns visible across Nova Scotia as previously described. Interested participants will be directed to the study's website (www.probioticstudy.com), where they will be able to view a complete summary of the study's timeline and details. After reviewing the website, guardians of potential participants will be able to complete an initial consent form and preliminary questionnaire in order to determine their child's eligibility for participation. The process of completing the consent form and initial questionnaires is expected to take approximately 15 minutes. Participants' responses to the preliminary questionnaire will be reviewed by the researchers, and initial appointments will be scheduled, either at the Acadia University location or the Halifax location.
Each participant will be enrolled in the study for a thirteen-week period with a six-month follow-up session. The first week will be an information-gathering week during which participants will complete a daily food diary online with their parents' assistance. Each evening during this initial week, and at the end of each week throughout the study period, the child will answer a few questions about his or her symptoms of anxiety and/or ADHD, and gastrointestinal health. Parents/guardians will answer parallel questions about the child's symptoms of anxiety and/or ADHD.
Confidentiality will be maintained by assigning each participant a code number based on the last four digits of their phone number and the first letter of their last name when they begin the study (for siblings the first letter of their first name will be used). The food diary and all other subsequent questionnaires will be matched with the participant's data via their code number. Participants or their guardians will be required to remember their individual code, although, in the event they forget their code number, a master list will be kept on an external hard-drive in an encrypted, password-protected file, locked in the researchers' office.
During or shortly after the food-diary week, the researcher will schedule a meeting with each participant and guardian in order to provide detailed instructions on the first phase of the study and to obtain informed consent for continuation in the study from the parent/guardian and assent from the child. During the first meeting parents/guardians will complete study outcome measures. Child participants will also complete outcome measures and cognitive tests. These measures will be administered once again following the completion of the first phase (week five), following the four-week wash-out period (week nine), and the second phase (week thirteen). These measures are the clinical trial's primary end-points.
Following the information-gathering week, participants will begin the first phase of the study. They will consume either the probiotic or placebo powder taken with milk or ice cream for four weeks. For the second phase, the conditions will be reversed, and the participant will consume the alternate substance for four weeks; thus, all participants will receive the probiotic in one phase and the placebo in another phase. The order in which participants receive the probiotics and placebo will be randomized within groups of ten participants to ensure counterbalancing - i.e., roughly equal numbers of participants receiving probiotics and placebo in the first phase. The four-week intervention phases will be separated by a four-week washout period to ensure that any potential residual effects from the first phase have passed by the time the second phase commences. Following the wash-out period, participants will complete the relevant outcome measures once again to establish baseline scores prior to beginning the second intervention phase. Because this a double-blind design, the participants, their parents/guardians and the researchers administering the probiotics and placebos will not be aware which powder (probiotic or placebo) the participant is receiving in each of the two phases; only the Clinical Director at Lallemand Health Solutions will be privy to the experimental condition of the participants. Morning saliva samples for cortisol analysis will be collected from participants during weeks two (baseline visit), five (second visit), nine (third visit), and thirteen (fourth visit) of the study.
During the first week of each phase, the researcher will contact the participants by email or phone on the third and sixth day to check in and make sure participants/their guardians do not have any concerns and/or questions regarding their participation. Following the initial week of each phase, participants will be contacted weekly in order to monitor progress and address any concerns.
During first and second meetings, parents will be supplied with either probiotic or placebo powder as well as detailed instructions for the first and second intervention phases. At the fourth and final appointment, participants will complete the aforementioned questionnaires (if not done online) and be given the opportunity to ask any questions they may have about the study. If participants wish to know during which phase they received the probiotic formula, they be supplied with this information following the completion of the study.
- Conditions
- Attention Deficit Hyperactivity Disorder, Anxiety
- Being tested
- L. helveticus R0052 and B. longum R0175, Placebo
- Keywords
- probiotic, ADHD, anxiety, digestive health, children, attention deficit, gut brain axis, nutritional supplement, microbiome
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
L. helveticus R0052 and B. longum R0175Dietary supplement
Also called Probiostick, Jamieson Probiotic Sticks, Health Canada Natural Product Number (NPN) 80021343
See arm descriptions for intervention description.
PlaceboOther
| Study group | Role | What they receive |
|---|---|---|
| Placebo powder | Placebo comparator | Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases. Receives: Other: Placebo |
| Probiotic powder | Experimental | The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases. Receives: Dietary Supplement: L. helveticus R0052 and B. longum R0175 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in ADHD-specific items of the Child Disruptive Behavior Disorders Scale
Measured: First day of study participation and again at weeks 4, 8, and 12
Secondary outcomes (5)
Change in Salivary cortisol
Measured: First day of study participation and again at weeks 4, 8, and 12
Change in total score on the Screen for Child Anxiety Related Emotional Disorders
Measured: First day of study participation and again at weeks 4, 8, and 12
Change in Word Pairs Memory Test
Measured: First day of study participation and again at weeks 4, 8, and 12
Change in Visual Memory Test
Measured: First day of study participation and again at weeks 4, 8, and 12
Change in total omission and commission errors on the Continuous Performance Task
Measured: First day of study participation and again at weeks 4, 8, and 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2015 (estimated)
- Study startJun 2015
- Primary completionMay 2016 (estimated)
- Study completionJun 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Attention Deficit Hyperactivity DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Acadia University
- Sponsor type
- University, hospital or other
- Collaborators
- Lallemand Health Solutions
- Responsible party
- Sponsor
- Investigators
- Susan Potter, Phd., Principal investigator, Acadia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02545634
- Sponsor's protocol ID
- APB-C1
- Status last verified
- Sep 2015
- First submitted
- 30 Jul 2015
- Last updated
- 10 Sep 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children
- ClinicalTrials.gov ID
- NCT02545634
- Acronym / sponsor ID
- APB-C1
- Conditions
- Attention Deficit Hyperactivity Disorder, Anxiety
- Keywords
- probiotic, ADHD, anxiety, digestive health, children, attention deficit, gut brain axis, nutritional supplement
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Acadia UniversityUniversity, hospital or other
- Collaborators
- Lallemand Health Solutions
- Study start
- Jun 2015
- Primary completion
- May 2016 (estimated)
- Study completion
- Jun 2016 (estimated)
- First posted
- 10 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will examine the effect of a probiotic supplement (Lactobacillus helveticus R0052 and Bifidobacterium Longum R0175) dissolved in a dairy product such as milk or ice-cream on symptoms of ADHD and anxiety in children. The main goal is to determine if probiotics might be useful as a treatment for anxiety and ADHD symptoms in children. A second goal is to examine the effects of probiotics on saliva cortisol levels. Finally, the investigators are also interested in the effects of the probiotics on children's digestive health.
Detailed description
Participants will be recruited using information distributed through schools in the Annapolis Valley area and with the use of advertising campaigns visible across Nova Scotia as previously described. Interested participants will be directed to the study's website (www.probioticstudy.com), where they will be able to view a complete summary of the study's timeline and details. After reviewing the website, guardians of potential participants will be able to complete an initial consent form and preliminary questionnaire in order to determine their child's eligibility for participation. The process of completing the consent form and initial questionnaires is expected to take approximately 15 minutes. Participants' responses to the preliminary questionnaire will be reviewed by the researchers, and initial appointments will be scheduled, either at the Acadia University location or the Halifax location.
Each participant will be enrolled in the study for a thirteen-week period with a six-month follow-up session. The first week will be an information-gathering week during which participants will complete a daily food diary online with their parents' assistance. Each evening during this initial week, and at the end of each week throughout the study period, the child will answer a few questions about his or her symptoms of anxiety and/or ADHD, and gastrointestinal health. Parents/guardians will answer parallel questions about the child's symptoms of anxiety and/or ADHD.
Confidentiality will be maintained by assigning each participant a code number based on the last four digits of their phone number and the first letter of their last name when they begin the study (for siblings the first letter of their first name will be used). The food diary and all other subsequent questionnaires will be matched with the participant's data via their code number. Participants or their guardians will be required to remember their individual code, although, in the event they forget their code number, a master list will be kept on an external hard-drive in an encrypted, password-protected file, locked in the researchers' office.
During or shortly after the food-diary week, the researcher will schedule a meeting with each participant and guardian in order to provide detailed instructions on the first phase of the study and to obtain informed consent for continuation in the study from the parent/guardian and assent from the child. During the first meeting parents/guardians will complete study outcome measures. Child participants will also complete outcome measures and cognitive tests. These measures will be administered once again following the completion of the first phase (week five), following the four-week wash-out period (week nine), and the second phase (week thirteen). These measures are the clinical trial's primary end-points.
Following the information-gathering week, participants will begin the first phase of the study. They will consume either the probiotic or placebo powder taken with milk or ice cream for four weeks. For the second phase, the conditions will be reversed, and the participant will consume the alternate substance for four weeks; thus, all participants will receive the probiotic in one phase and the placebo in another phase. The order in which participants receive the probiotics and placebo will be randomized within groups of ten participants to ensure counterbalancing - i.e., roughly equal numbers of participants receiving probiotics and placebo in the first phase. The four-week intervention phases will be separated by a four-week washout period to ensure that any potential residual effects from the first phase have passed by the time the second phase commences. Following the wash-out period, participants will complete the relevant outcome measures once again to establish baseline scores prior to beginning the second intervention phase. Because this a double-blind design, the participants, their parents/guardians and the researchers administering the probiotics and placebos will not be aware which powder (probiotic or placebo) the participant is receiving in each of the two phases; only the Clinical Director at Lallemand Health Solutions will be privy to the experimental condition of the participants. Morning saliva samples for cortisol analysis will be collected from participants during weeks two (baseline visit), five (second visit), nine (third visit), and thirteen (fourth visit) of the study.
During the first week of each phase, the researcher will contact the participants by email or phone on the third and sixth day to check in and make sure participants/their guardians do not have any concerns and/or questions regarding their participation. Following the initial week of each phase, participants will be contacted weekly in order to monitor progress and address any concerns.
During first and second meetings, parents will be supplied with either probiotic or placebo powder as well as detailed instructions for the first and second intervention phases. At the fourth and final appointment, participants will complete the aforementioned questionnaires (if not done online) and be given the opportunity to ask any questions they may have about the study. If participants wish to know during which phase they received the probiotic formula, they be supplied with this information following the completion of the study.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo powder | Placebo comparator | Other: PlaceboPlacebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases. |
| Probiotic powder | Experimental | Dietary Supplement: L. helveticus R0052 and B. longum R0175The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases. |
Who may qualify
- Ages
- 6 to 14 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- average score of 2.5 or higher on either the hyperactive/impulsive or inattentive symptoms on eligibility questionnaire
- total score of 10 or higher on the anxiety eligibility questionnaire
Key exclusion criteria (5 listed)
- Dairy or Soy allergy
- Currently taking antibiotics
- HIV/AIDS
- Diagnosis of Cancer, Crohn's Disease, or Ulcerative Colitis
- Undergoing chemotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| L. helveticus R0052 and B. longum R0175Also: Probiostick, Jamieson Probiotic Sticks, Health Canada Natural Product Number (NPN) 80021343See arm descriptions for intervention description. | Dietary supplement | Probiotic powder |
| Placebo | Other | Placebo powder |
Primary outcome
Change in ADHD-specific items of the Child Disruptive Behavior Disorders Scale
Time frame: First day of study participation and again at weeks 4, 8, and 12
5 secondary outcomes
Change in Salivary cortisol
Time frame: First day of study participation and again at weeks 4, 8, and 12
Change in total score on the Screen for Child Anxiety Related Emotional Disorders
Time frame: First day of study participation and again at weeks 4, 8, and 12
Change in Word Pairs Memory Test
Time frame: First day of study participation and again at weeks 4, 8, and 12
Change in Visual Memory Test
Time frame: First day of study participation and again at weeks 4, 8, and 12
Change in total omission and commission errors on the Continuous Performance Task
Time frame: First day of study participation and again at weeks 4, 8, and 12
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2015.
Related trials for Attention Deficit Hyperactivity Disorder
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
ADHD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Susan Potter, Phd. principal investigator
Acadia University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing L. helveticus R0052 and B. longum R0175 in people with Attention Deficit Hyperactivity Disorder and Anxiety, run by Acadia University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Susan Potter, Phd. (902-585-1220, susan.potter@acadiau.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in ADHD-specific items of the Child Disruptive Behavior Disorders Scale (time frame: First day of study participation and again at weeks 4, 8, and 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2015.